Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01071005
Recruitment Status : Completed
First Posted : February 18, 2010
Last Update Posted : February 25, 2013
Information provided by:
Azidus Brasil

Brief Summary:

The primary objective of this study is to examine, in healthy subjects, the comparative pharmacodynamics of Lorelin Depot (leuprorelin), manufactured by the Chemical Pharmaceutical Laboratory Bergamo Ltda with the product Lupron Depot ® (leuprorelin), manufactured by Abbott Laboratories Ltd, through the strength of biological markers follicle stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone, associated with the activity of the substance.

Secondarily be observed safety (tolerability) of subjects in clinical research through the comparison of clinical and laboratory parameters pre-and post-study, and incidence of adverse events.

Condition or disease Intervention/treatment Phase
Healthy Drug: Lorelin Depot Bergamo Drug: Lupron Depot - Abbott Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial of the Pharmacodynamics of Lorelin Depot 3.75Mg (Leuprorelin Acetate) Produced by Laboratório Químico Farmacêutico Bergamo LTDA. Compared to Lupron Depot ® 3.75 Mg Produced by Abbott in Healthy Subjects
Study Start Date : August 2010
Actual Primary Completion Date : October 2010
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Arm Intervention/treatment
Experimental: Test
Lorelin Depot - Bergamo
Drug: Lorelin Depot Bergamo
Lorelin Depot Bergamo, 3,75 mg, single dose.

Active Comparator: comparator
Lupron Depot® - Abbott
Drug: Lupron Depot - Abbott
Lupron Depot 3,75 mg, single dose.

Primary Outcome Measures :
  1. Decrease of serum levels of luteinizing hormone, Testosterone and FSH [ Time Frame: 56 days ]

Secondary Outcome Measures :
  1. Evaluation of safety through the adverse affects investigation [ Time Frame: 56 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Accept the Informed Consent.
  2. Subjects of research males aged 40 to 45 years;
  3. Subject of research with body mass index greater than or equal to 19 and less than or equal to 30;
  4. Be considered healthy, from the analysis of the clinical history and medical examination;
  5. Laboratory tests with results outside the values considered normal, but not considered clinically relevant.

Exclusion Criteria:

  1. Have donated or lost 450 mL or more of blood in the three months preceding the study;
  2. Have participated in any experimental study or have taken any experimental drug in the last three months prior to the start of the study;
  3. Have made regular use of medication in the last 4 weeks prior to the start of the study or have made use of any medication a week before the study began;
  4. Have been hospitalized for any reason, up to 8 weeks before the study;
  5. Provide history of alcohol abuse, drugs or medications, or have ingested alcohol within 48 hours prior to the period of hospitalization;
  6. Have a history of liver disease, renal, pulmonary, gastrointestinal, hematological or psychiatric;
  7. Amendments pressure of any etiology requiring pharmacological treatment;
  8. Present history of myocardial infarction, angina and / or heart failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01071005

Lal Clinica Pesquisa E Desenvolvimento Ltda
Valinhos, SP, Brazil, 13270000
Sponsors and Collaborators
Azidus Brasil

Responsible Party: Alexandre Frederico, LAL Clinica Pesquisa e Desenvolvimento Ltda Identifier: NCT01071005     History of Changes
Other Study ID Numbers: LEUBER0409
Versão 03 - Emenda 1
First Posted: February 18, 2010    Key Record Dates
Last Update Posted: February 25, 2013
Last Verified: February 2013

Keywords provided by Azidus Brasil:
Decrease serum levels of luteinizing hormone, FSH and Testosterone

Additional relevant MeSH terms:
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents